Bicalutamide ('Casodex') 150mg in addition to standard care in patients with nonmetastatic prostate cancer: Updated results from a randomised double-blind phase III study (median follow-up 5.1y) in the early prostate cancer programme

Simple item page
dc.contributor.authorWirth M.
dc.contributor.authorTyrrell C.
dc.contributor.authorDelaere K.
dc.contributor.authorSanchez-Chapado M.
dc.contributor.authorRamon J.
dc.contributor.authorWallace D.M.A.
dc.contributor.authorHetherington J.
dc.contributor.authorPina F.
dc.contributor.authorHeyns C.
dc.contributor.authorBorchers T.
dc.contributor.authorMorris T.
dc.contributor.authorArmstrong J.
dc.date.accessioned2011-05-15T16:17:46Z
dc.date.available2011-05-15T16:17:46Z
dc.date.issued2005
dc.description.abstractTrial 24 is one of three placebo-controlled trials within the ongoing bicalutamide ('Casodex'+) Early Prostate Cancer (EPC) programme evaluating bicalutamide 150mg/day in addition to radical prostatectomy, radiotherapy or watchful waiting for T1b -4, any N, M0 prostate cancer. In Trial 24, at 5.1y median follow-up, the addition of bicalutamide significantly (P<0.0001) improved objective progression-free survival (PFS) and prostate-specific antigen PFS compared with standard care alone. There was no significant difference in overall survival (P = 0.746). In the context of the whole EPC programme, long-term bicalutamide is not appropriate for localised disease, yet provides advantages in delaying disease progression in patients with locally advanced prostate cancer. © 2005 Nature Publishing Group. All rights reserved.
dc.description.versionArticle
dc.identifier.citationProstate Cancer and Prostatic Diseases
dc.identifier.citation8
dc.identifier.citation2
dc.identifier.issn13657852
dc.identifier.other10.1038/sj.pcan.4500799
dc.identifier.urihttp://hdl.handle.net/10019.1/14361
dc.subjectbicalutamide
dc.subjectplacebo
dc.subjectprostate specific antigen
dc.subjectanilide
dc.subjectantineoplastic agent
dc.subjectaccidental injury
dc.subjectadd on therapy
dc.subjectadvanced cancer
dc.subjectarthralgia
dc.subjectarticle
dc.subjectbackache
dc.subjectbody weight disorder
dc.subjectcancer growth
dc.subjectcancer radiotherapy
dc.subjectcancer staging
dc.subjectcancer survival
dc.subjectclinical trial
dc.subjectconstipation
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectdisease free survival
dc.subjectdouble blind procedure
dc.subjectfollow up
dc.subjectgynecomastia
dc.subjecthematuria
dc.subjecthernia
dc.subjecthot flush
dc.subjecthuman
dc.subjecthypercholesterolemia
dc.subjectimpotence
dc.subjectlong term care
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmastalgia
dc.subjectpain
dc.subjectpatient care
dc.subjectphase 3 clinical trial
dc.subjectpriority journal
dc.subjectprostate cancer
dc.subjectprostatectomy
dc.subjectrandomized controlled trial
dc.subjectrash
dc.subjectsomnolence
dc.subjectstatistical analysis
dc.subjecturinary tract infection
dc.subjecturine incontinence
dc.subjectweight gain
dc.subjectadult
dc.subjectaged
dc.subjectmiddle aged
dc.subjectmulticenter study
dc.subjectprostate tumor
dc.subjectsurvival
dc.subjecttreatment outcome
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAnilides
dc.subjectAntineoplastic Agents
dc.subjectDouble-Blind Method
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPlacebos
dc.subjectProstatectomy
dc.subjectProstatic Neoplasms
dc.subjectSurvival Analysis
dc.subjectTreatment Outcome
dc.titleBicalutamide ('Casodex') 150mg in addition to standard care in patients with nonmetastatic prostate cancer: Updated results from a randomised double-blind phase III study (median follow-up 5.1y) in the early prostate cancer programme
dc.typeArticle
Files
Collections
Stellenbosch University - Scopus Tygerberg Hospital Publications